These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
980 related articles for article (PubMed ID: 22659218)
1. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218 [TBL] [Abstract][Full Text] [Related]
2. Optimization of adefovir therapy in chronic hepatitis B according to baseline predictors and on-treatment HBV DNA: a 5-year prospective study. Lu H; Geng da Y; Shen F; Zhang JY; Lu B; Ma LX Virol J; 2011 Sep; 8():444. PubMed ID: 21936898 [TBL] [Abstract][Full Text] [Related]
3. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020 [TBL] [Abstract][Full Text] [Related]
4. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735 [TBL] [Abstract][Full Text] [Related]
5. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Takkenberg RB; Jansen L; de Niet A; Zaaijer HL; Weegink CJ; Terpstra V; Dijkgraaf MG; Molenkamp R; Jansen PL; Koot M; Rijckborst V; Janssen HL; Beld MG; Reesink HW Antivir Ther; 2013; 18(7):895-904. PubMed ID: 23639931 [TBL] [Abstract][Full Text] [Related]
6. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773 [TBL] [Abstract][Full Text] [Related]
7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546 [TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. Moucari R; Boyer N; Ripault MP; Castelnau C; Mackiewicz V; Dauvergne A; Valla D; Vidaud M; Chanoine MH; Marcellin P J Viral Hepat; 2011 Aug; 18(8):580-6. PubMed ID: 20487260 [TBL] [Abstract][Full Text] [Related]
10. HBsAg clearance by Peg-interferon addition to a long-term nucleos(t)ide analogue therapy. Barone M; Iannone A; Di Leo A World J Gastroenterol; 2014 Jul; 20(26):8722-5. PubMed ID: 25024631 [TBL] [Abstract][Full Text] [Related]
11. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study. Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F; Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270 [TBL] [Abstract][Full Text] [Related]
12. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B. Wong D; Littlejohn M; Edwards R; Jackson K; Revill P; Gaggar A; Kitrinos K; Subramanian M; Marcellin P; Buti-Ferret M; Janssen H; Gane E; Locarnini S; Thompson A Liver Int; 2018 Oct; 38(10):1760-1769. PubMed ID: 29427368 [TBL] [Abstract][Full Text] [Related]
13. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. Stelma F; van der Ree MH; Jansen L; Peters MW; Janssen HLA; Zaaijer HL; Takkenberg RB; Reesink HW J Viral Hepat; 2017 Dec; 24(12):1107-1113. PubMed ID: 28632898 [TBL] [Abstract][Full Text] [Related]
14. Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. Gara N; Tana MM; Kattapuram M; Auh S; Sullivan L; Fryzek N; Walter M; Umarova R; Zhao X; Cloherty G; Doo E; Heller T; Liang TJ; Ghany MG Hepatol Commun; 2021 Nov; 5(11):1888-1900. PubMed ID: 34558806 [TBL] [Abstract][Full Text] [Related]
15. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126 [TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients. Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833 [TBL] [Abstract][Full Text] [Related]
17. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403 [TBL] [Abstract][Full Text] [Related]
18. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study. Maklad S; Doss W; El Din SS; Hassan K; Zeid AA Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505 [TBL] [Abstract][Full Text] [Related]
19. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899 [TBL] [Abstract][Full Text] [Related]
20. Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. Hsu CW; Su WW; Lee CM; Peng CY; Chuang WL; Kao JH; Chu HC; Huang YH; Chien RN; Liaw YF J Formos Med Assoc; 2018 Jul; 117(7):588-597. PubMed ID: 29456079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]